Recently, there have been effective applications of novel medicines that specifically target the surface expression of programmed cell death-1 (PD-1)/PD-L1 in the treatment of various solid malignancies, such as melanoma (Han et al., 2020). The gene discussed is PDCD1; the disease is melanoma.